"In patients receiving combination OPT-302 + Lucentis®, the proportion gaining ≥5, ≥10 or ≥15 letters of vision from baseline to week 12 was 67%, 44% and 33% respectively in treatment-naïve subjects (baseline mean best corrected visual acuity (BCVA) 56.4 letters) while it was 53%, 16% and 0% for patients previously treated with multiple intravitreal anti-VEGF-A agents (baseline mean BCVA 64.5 letters)"
I'm not sure how to judge their prelim results - Obviously more letters wererestored in the treatment naive group vs groups that previously received Lucentis, but the BCVA was also lower for the treatment naive group (almost 20% lower). One might expect a lower BCVA i.e. a worse eye easier to treat and improve? So which is better?
"In patients receiving combination OPT-302 + Lucentis®, the...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
-0.005(1.32%) |
Mkt cap ! $409.3M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 39.0¢ | 37.3¢ | $628.5K | 1.669M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 33 | 313589 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 31403 | 3 |
View Market Depth
| Last trade - 14.37pm 16/07/2024 (20 minute delay) ? |
| OPT (ASX) Chart |